You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 62 No. 4, April 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (30)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Schizophrenia
 •Alert me on articles by topic

Increased Caudate Dopamine D2 Receptor Availability as a Genetic Marker for Schizophrenia

Jussi Hirvonen, MD; Theo G. M. van Erp, MA; Jukka Huttunen, MD; Sargo Aalto, MSc; Kjell Någren, PhD; Matti Huttunen, MD, PhD; Jouko Lönnqvist, MD, PhD; Jaakko Kaprio, MD, PhD; Jarmo Hietala, MD, PhD; Tyrone D. Cannon, PhD

Arch Gen Psychiatry. 2005;62:371-378.

Context  Schizophrenia has a heritability of about 80%, but the detailed molecular genetic basis of the disorder has remained elusive. Relative hyperfunction of the subcortical dopamine system has been previously suggested to be one of the key pathophysiologic mechanisms in schizophrenic psychosis.

Objective  To examine the contributions of genetic vulnerability for schizophrenia to the dopamine system in the human brain.

Design  Population-based twin cohort study.

Setting  Finland.

Participants  Six monozygotic and 5 dizygotic unaffected co-twins of patients with schizophrenia were ascertained, along with 4 monozygotic and 3 dizygotic healthy control twins with no family history of psychotic disorders.

Main Outcome Measures  Striatal dopamine D2 receptor availability estimated with positron emission tomographic imaging and carbon 11 (11C)–labeled raclopride, and performance on neuropsychological tests sensitive to frontal lobe functioning and to schizophrenia vulnerability.

Results  Unaffected monozygotic co-twins had increased caudate D2 density compared with unaffected dizygotic co-twins and healthy control twins. Higher D2 receptor binding in caudate was associated with a poor performance on cognitive tasks related to schizophrenia vulnerability in the whole sample.

Conclusions  The caudate dopamine D2 receptor up-regulation is related to genetic risk for schizophrenia. Higher dopamine D2 receptor density in caudate is also associated with poorer performance on cognitive tasks involving corticostriatal pathways. This finding suggests that caudate dopamine dysregulation is also a trait phenomenon related to psychosis vulnerability. This pattern of results provides a theoretical rationale for early pharmacologic intervention approaches using dopamine D2 receptor blocking drugs.


Author Affiliations: Departments of Pharmacology and Clinical Pharmacology (Dr Hirvonen) and Psychiatry (Drs J. Huttunen and Hietala), Centre for Cognitive Neuroscience (Mr Aalto), and Turku PET Centre (Drs Hirvonen, J. Huttunen, Någren, and Hietala), University of Turku, Turku, Finland; Departments of Psychology, Psychiatry, and Human Genetics, University of California at Los Angeles School of Medicine (Mr van Erp and Dr Cannon); Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland (Drs M. Huttunen, Lönnqvist and Kaprio); and Department of Public Health, University of Helsinki (Dr Kaprio).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis
HOWES et al.
Br. J. Psychiatry 2007;191:s13-s18.
ABSTRACT | FULL TEXT  

Evidence That the BLOC-1 Protein Dysbindin Modulates Dopamine D2 Receptor Internalization and Signaling But Not D1 Internalization
Iizuka et al.
J. Neurosci. 2007;27:12390-12395.
ABSTRACT | FULL TEXT  

Brain Dopamine D1 Receptors in Twins Discordant for Schizophrenia
Hirvonen et al.
Am. J. Psychiatry 2006;163:1747-1753.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.